- Home
- CEVA vs RIGL Comparison
CEVA vs RIGL Comparison
Compare CEVA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CEVA | RIGL |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 683.2M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CEVA | RIGL |
|---|---|---|
| Price | $19.69 | $36.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $33.25 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 339.9K | 250.8K |
| Earning Date | 05-19-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.45 | ★ 807.14 |
| EPS | N/A | ★ 5.38 |
| Revenue | $87,507,000.00 | ★ $179,278,000.00 |
| Revenue This Year | $14.97 | $66.81 |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | ★ N/A | $6.64 |
| Revenue Growth | 20.45 | ★ 53.38 |
| 52 Week Low | $18.23 | $15.50 |
| 52 Week High | $36.95 | $52.24 |
Technical Indicators
Market Signals| Indicator | CEVA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 50.10 |
| Support Level | $19.30 | $33.23 |
| Resistance Level | $24.00 | $34.99 |
| Average True Range (ATR) | 1.25 | 1.46 |
| MACD | -0.23 | 0.39 |
| Stochastic Oscillator | 8.21 | 97.78 |
Price Performance
Historical ComparisonAbout CEVA CEVA Inc.
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.